drugset / Trial / NCT00405886

Neramexane for Tinnitus

NCT00405886 ↗

Phase 2 Completed 431 enrolled Merz Pharmaceuticals GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Tinnitus is commonly referred to as "ringing of the ears" - the perception of sounds in the absence of an external source of acoustic signals. Tinnitus may represent a severe disease and symptoms include depression, sleeping difficulties, decreased sound tolerance and hearing loss. One hypothesis is that tinnitus is caused by an increased activity of NMDA glutamate and dysfunctional alpha9/alpha10 acetylcholine receptors in the inner ear and central nervous system. Neramexane may alleviate tinnitus symptoms due to its NMDA and alpha9/alpha10 nACh receptor blocking activity. The purpose of this study is to assess the safety and efficacy of Neramexane compared with placebo in patients with subjective tinnitus.

Timeline

Start
2005-10
Primary completion
2007-03
Completion
2007-03

Outcome

Missed primary endpoint

paper This treatment difference did not reach statistical significance at the pre-defined endpoint in Week 16 (p = 0.098 for 50 mg/d; p = 0.289 for 75 mg/d neramexane) PMID 21223542 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Neramexane Small molecule 25 mg Oral
Subject Neramexane Small molecule 50 mg Oral
Subject Neramexane Small molecule 75 mg Oral

Indications